Document is current
Any future updates will be listed below
-
Authors
Ben Sassi, Mehdi
Azais, Henri
Marcaillou, Charles
Guibert, Sylvain
Martin, Emmanuel
Alexandre, Jérôme
Benoit, Louise
de Reynies, Aurélien
Laude, Emilie
Duong, Cam
Medioni, Jacques
Borghese, Bruno
Bats, Anne-Sophie
Taly, Valerie
Laurent-Puig, Pierre
-
Funding
Funding for this research was provided by:
Association Nationale de la Recherche et de la Technologie
- License Information
-
More Information
Article History
Received: 14 February 2025
Accepted: 30 May 2025
First Online: 12 June 2025
Declarations
:
: Study protocol was approved by an ethic committee (Comité de Protection des Personnes– Ile de France II », Research number: 2013-10-01 MS1, Biovaire Study n° ID-RCB: 2013-A01108-37. All patients recruited in the study signed an informed written consent.
: Not applicable.
: For PLP: President of Canceropole Ile de France; Director of the « Institut du cancer Paris Carpem; Speaker, Consultancy or Advisory role for Biocartis; Pierre Fabre; BMS; Servier; MSD; Founder and ownership interests in Methys Dx. For MBS, CM, SG and EM: employees at Integragen SA. For HA: Speaker, Consultancy or Advisory role for GlaxoSmithKline. VT: Founder, president and Chief scientific officer, and ownership interests in Methys Dx.
